Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 9/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14950261 | 0.89 | FAAH (0.53) | FAAHCES2MCHR1CYP2D6TGFBR1 | |
| SCHEMBL427732 | 0.89 | FAAH (0.53) | FAAHCES2MCHR1CYP2D6TGFBR1 | |
| SCHEMBL427057 | 0.89 | FAAH (0.63) | FAAHCES2MCHR1MAP4K4NPC1 | |
| SCHEMBL427361 | 0.88 | FAAH (0.52) | FAAHCES2CYP46A1TGFBR1PDE4B | |
| SCHEMBL425811 | 0.88 | FAAH (0.65) | FAAHCES2MCHR1MAP4K4NPC1 | |
| SCHEMBL427868 | 0.88 | FAAH (0.59) | FAAHCES2TGFBR1NPC1RAB9A | |
| SCHEMBL427369 | 0.88 | FAAH (0.49) | FAAHCES2TGFBR1PDE4B | |
| SCHEMBL426220 | 0.87 | FAAH (0.53) | FAAHCES2MCHR1CYP2D6CYP46A1 | |
| SCHEMBL426156 | 0.86 | FAAH (0.50) | FAAHCES2MCHR1NPC1RAB9A | |
| SCHEMBL424911 | 0.86 | FAAH (0.48) | FAAHCES2MCHR1CYP2D6TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606035-B1 | PROCES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA S A (PT) | 2017-09-06 | — | — | EP | disclosed |
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | UTS2R, ARG1, PRMT1 | FAAH 2166/4885CES2 463/4885MCHR1 1489/4885 |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885CES2 62/4885MCHR1 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.